| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 108.66 | 22.5% | 12.8% |
| Total Income | 110.36 | 21.6% | 12.5% |
| Expenditure | 104.31 | 14.5% | 12.9% |
| PBT | 6.05 | 1858.8% | 6.0% |
| Net Profit | 4.40 | 1135.7% | 9.9% |
| OPM | 11.79% | 5.31pp | 15.59pp |
| NPM | 3.98% | 4.45pp | 0.10pp |
| EPS | 0.90 | 900.0% | 9.8% |
Zim Laboratories Ltd. Announces Q3 Results with 10.87 Billion Revenue and Approves Investment in Chile Subsidiary
11 Feb 2026 · 11 Feb, 7:03 pm
Summary
Zim Laboratories Ltd. has announced its Q3 results with a revenue of 10.87 billion. The company has also approved an investment of up to USD 15,000 for incorporating a wholly owned subsidiary in Chile, LATAM region. The decision was made in a Board Meeting held on 11th February, 2026.
Key Highlights
- 1
Q3 revenue of 10.87 billion
- 2
Approval for investment in Chile subsidiary
- 3
Investment amount of up to USD 15,000
Management Comments
N
Name of the Person
Comment of the Person
Informational and educational content only. Not investment advice.